News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
TMX Newsfile
NEWS
IN THE PRESS
BioMidwest
RxLightning Achieves Microsoft IP Co-Sell Ready Partner Status
June 29, 2021
·
1 min read
Pharm Country
Portage Biotech Added to Russell 2000(R) Index
June 29, 2021
·
3 min read
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy
June 29, 2021
·
4 min read
NanoPsy Inc. Closes Seed Round, Funds to Be Used to Prove Efficacy of Nanobowl Technology with Ketamine and LSD
June 29, 2021
·
3 min read
Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer
June 29, 2021
·
4 min read
Biotech Bay
Humanigen Inc. Added to Russell 3000(R) Index
June 28, 2021
·
4 min read
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT
June 28, 2021
·
3 min read
BioCure Technology Inc. Commences Dual Listing in Germany and Announces New Contracts
June 28, 2021
·
4 min read
Therma Bright Secures US Distributor ‘DME Authority’ for Its Patented Venowave Lightweight Deep Vein Thrombosis (DVT) Device, Just as US Healthcare Providers Deal with Device Shortages
June 28, 2021
·
10 min read
Awakn Life Sciences Files Patent Applications in U.S. for AWKN001 and AWKN002, Two Next-Generation New Chemical Entities [NCES] to Treat a Broad Range of Addiction Indications
June 28, 2021
·
5 min read
15 Toronto St., Suite 601 Toronto ON M5C 2E3 US
Tel: 416-806-1750
Visit website
Email Us